RI
NBIX icon

RTW Investments’s Neurocrine Biosciences NBIX Stock Holding History

RTW Investments’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214M Buy
1,267,925
+205,853
+19% +$30.5M 1.82% 20
2026
Q1 		$140M Hold
1,062,072
– – 1.39% 24
2025
Q4 		$151M Hold
1,062,072
– – 1.51% 22
2025
Q3 		$149M Hold
1,062,072
– – 1.84% 18
2025
Q2 		$133M Buy
+1,062,072
New +$122M 1.9% 19

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

RTW Investments's NBIX Position: Q2 2026 in Review

RTW Investments increased its Neurocrine Biosciences (NBIX) stake by 19% in Q2 2026, buying an estimated $30.5M and bringing the position to 1,267,925 shares worth $214M. The position accounts for 1.82% of the portfolio, ranked #20.

RTW Investments first reported a position in NBIX in Q2 2025 and has held it in 5 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • RTW Investments held 1,267,925 shares of Neurocrine Biosciences worth $214M as of Q2 2026.
  • RTW Investments bought 205,853 Neurocrine Biosciences shares in Q2 2026, an estimated $30.5M.
  • Neurocrine Biosciences made up 1.82% of RTW Investments's portfolio in Q2 2026, its #20 holding.
  • RTW Investments first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 5 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on RTW Investments's 13F filing for Q2 2026, filed 14 Aug 2026.